핵의약학 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별(의료기관용, 상업용), 용도별(진단용, 치료용), 지역별 세분화 및 경쟁 구도(2020-2030년)

The Global Nuclear Pharmacy Market, valued at USD 5.99 Billion in 2024, is projected to experience a CAGR of 7.92% to reach USD 9.46 Billion by 2030. Nuclear pharmacy involves the preparation and dispensing of radioactive materials for patient administration in nuclear medicine, utilizing radiopharmaceuticals for diagnostic and therapeutic purposes. Market growth is driven by the increasing prevalence of chronic diseases like cancer and cardiovascular disorders, advancements in nuclear medicine technologies, and a growing demand for personalized medicine, expanding applications across oncology and neurology.

Key Market Drivers

The global nuclear pharmacy market is significantly influenced by two major driving factors: the rising burden of chronic diseases and continuous advancements in radiopharmaceutical development. The increasing global burden of chronic diseases represents a primary impetus for the nuclear pharmacy market, necessitating sophisticated diagnostic and therapeutic interventions. Conditions like cancer, cardiovascular disorders, and neurodegenerative diseases exhibit growing prevalence worldwide, driving escalating demand for early, accurate detection and targeted treatment. Nuclear medicine, offering functional and molecular imaging, proves crucial in disease staging, treatment monitoring, and personalized therapy selection.

Key Market Challenges

A significant challenge impeding the Global Nuclear Pharmacy Market's growth is the persistent supply chain disruptions and shortages of critical radioisotopes. The inherently short half-lives of these materials, such as Technetium-99m, necessitate complex and highly efficient logistics, making the supply chain exceptionally vulnerable to any interruption in production or distribution. This reliance on a limited number of aging nuclear reactors for isotope generation, coupled with unpredictable maintenance schedules or unexpected outages, frequently leads to insufficient supply.

Key Market Trends

The emergence of targeted alpha therapies significantly influences the global nuclear pharmacy market by introducing a potent and precise cancer treatment modality. These therapies deliver highly localized radiation using alpha-emitting isotopes, effectively targeting malignant cells with minimal damage to healthy tissues, thus expanding therapeutic options. In January 2025, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) strategy meeting indicated two-thirds of physicians anticipated over 10% growth in therapy at their facilities within the year. This is reinforced by Sanofi's AlphaMedix (Lead-212-DOTAMTATE) receiving FDA Breakthrough Therapy Designation in February 2024, followed by positive Phase 2 results for gastroenteropancreatic neuroendocrine tumors in October 2025.

Key Market Players

• Jubilant Radiopharma (Jubilant Pharma Holdings Inc.)
• GE HealthCare Technologies, Inc.
• Cardinal Health, Inc.
• ARTMS Inc.
• AnazaoHealth Corp.
• Sofie Biosciences, Inc.
• Pacific Radiopharmacy, Ltd.
• NTP Radioisotopes SOC Ltd.
• Lantheus Medical Imaging, Inc.
• ANSTO Nuclear Medicine Pty Ltd.

Report Scope:

In this report, the Global Nuclear Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Pharmacy Market, By Type:

• Institutional
• Commercial

Nuclear Pharmacy Market, By Purpose:

• Diagnostic
• Therapeutic

Nuclear Pharmacy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nuclear Pharmacy Market.

Available Customizations:

Global Nuclear Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Pharmacy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Institutional, Commercial)
  • 5.2.2. By Purpose (Diagnostic, Therapeutic)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nuclear Pharmacy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Purpose
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nuclear Pharmacy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Purpose
  • 6.3.2. Canada Nuclear Pharmacy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Purpose
  • 6.3.3. Mexico Nuclear Pharmacy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Purpose

7. Europe Nuclear Pharmacy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Purpose
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nuclear Pharmacy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Purpose
  • 7.3.2. France Nuclear Pharmacy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Purpose
  • 7.3.3. United Kingdom Nuclear Pharmacy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Purpose
  • 7.3.4. Italy Nuclear Pharmacy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Purpose
  • 7.3.5. Spain Nuclear Pharmacy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Purpose

8. Asia Pacific Nuclear Pharmacy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Purpose
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nuclear Pharmacy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Purpose
  • 8.3.2. India Nuclear Pharmacy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Purpose
  • 8.3.3. Japan Nuclear Pharmacy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Purpose
  • 8.3.4. South Korea Nuclear Pharmacy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Purpose
  • 8.3.5. Australia Nuclear Pharmacy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Purpose

9. Middle East & Africa Nuclear Pharmacy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Purpose
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nuclear Pharmacy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Purpose
  • 9.3.2. UAE Nuclear Pharmacy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Purpose
  • 9.3.3. South Africa Nuclear Pharmacy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Purpose

10. South America Nuclear Pharmacy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Purpose
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nuclear Pharmacy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Purpose
  • 10.3.2. Colombia Nuclear Pharmacy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Purpose
  • 10.3.3. Argentina Nuclear Pharmacy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Purpose

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nuclear Pharmacy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Jubilant Radiopharma (Jubilant Pharma Holdings Inc.)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GE HealthCare Technologies, Inc.
• 15.3. Cardinal Health, Inc.
• 15.4. ARTMS Inc.
• 15.5. AnazaoHealth Corp.
• 15.6. Sofie Biosciences, Inc.
• 15.7. Pacific Radiopharmacy, Ltd.
• 15.8. NTP Radioisotopes SOC Ltd.
• 15.9. Lantheus Medical Imaging, Inc.
• 15.10. ANSTO Nuclear Medicine Pty Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer